 Acyclovir therapy neonates STUDY OBJECTIVE pharmacokinetic parameters acyclovir disposition neonates renal dysfunction DESIGN Prospective sequential open enrollment neonates presumed herpes group virus infections SETTING Neonatal intensive care units Paul metropolitan area PATIENTS Sixteen neonates gestational ages weeks median weeks acyclovir days life presumed herpes virus infections infants ill multisystem disease infants hepatic failure underwent blood exchange transfusion infants renal failure mean range serum acyclovir concentrations patient radioimmunoassay Pharmacokinetic parameters acyclovir concentrations samples patients MEASUREMENTS MAIN RESULTS pharmacokinetic disposition acyclovir two-compartment model ranges acyclovir clearance terminal elimination beta wide significant relationship clearance beta versus serum creatinine concentration average beta infants serum creatinine level mg/dl mumol/L hours hours serum creatinine level mg/dl CONCLUSIONS Neonates hepatic renal dysfunction young premature infants acyclovir adjustment organ dysfunction Measurement serum creatinine creatinine clearance useful dosing acyclovir neonates